Clinicopathological and survival analysis of endometrial carcinoma: a single center experience in Pakistan

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Endometrial Cancer
Pathology/Molecular Biology
Presenter Zarka Samoon
Citation Annals of Oncology (2018) 29 (suppl_9): ix74-ix78. 10.1093/annonc/mdy435
Authors Z. Samoon1, S. Ahmed1, S. Jehangir1, S.F. Rizvi1, S. Sawani2
  • 1Oncology, The Aga Khan University Hospital, 74800 - Karachi/PK
  • 2Community Medicine, The Aga Khan University Hospital, 74800 - Karachi/PK



Endometrial carcinoma is the most common malignancy of the female genital tract. Adjuvant chemotherapy sequentially with radiation has shown to improve progression free survival in previous studies.


From 12 March 2005 till 15 June 2016, 239 patients with Endometrial Cancer treated at Aga Khan University Hospital, Karachi were identified and retrospectively reviewed for survival analysis. We aimed to determine the progression free survival and overall survival of patients with Endometrial Cancer and factors affecting them.


The mean age at tumor diagnosis was 60.2 ±10.53 years. One hundred and thirty four (56.30%) patients had T1a tumor size and 120 (50.21%) patients had histological Stage IA disease. The most common histopathology was endometroid (81.56%). One hundred and nineteen (49.79%) patients had Grade II, and 62 (25.94%) had grade III disease. Fourteen patients (5.86%) presented with metastatic disease, with lung (50%) being the most common site involved. Surgery was done in 184 patients (94.36%), with complete debulking in 166 patients (90.22%). Adjuvant chemotherapy was received by 40 patients (20.51%) whereas adjuvant radiation therapy was received by 88 patients (45.13%) . Median progression free survival was 30.56 months and median overall survival was 27.34 months. Grade II tumors were associated with improved survival (101 months P = 0.035). Among patients 86.15% of the patients showed no evidence of progression, where as 13.85% of the patients had documented progression.


The patient population primarily had early stage disease with endometrioid histology. The five year progression free survival and overall survival was 75% and 94% respectively.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.